Panax notoginseng (san qi) is a ginseng relative used in Chinese medicine. Most clinical research is from China and uses Chinese products made from its saponins, often given by injection, rather than supplements.
Also known as: notoginseng, san qi, tian qi, Xuesaitong.
A Chinese stroke trial used Xuesaitong soft capsules (notoginseng saponins) at 120 mg twice a day for 3 months (Wu 2023). These are study protocols, not a recommendation.
It is sold in the US as a dietary supplement. Under the 1994 dietary supplement law (DSHEA), FDA does not approve dietary supplements before they are marketed, and the maker, not FDA, is responsible for safety and labeling.
What studies show: in a placebo-controlled trial at 67 Chinese hospitals, 2,966 adults with ischemic stroke who took notoginseng saponin capsules within 14 days were more likely to be functionally independent at 3 months (89.3% versus 82.4%) (Wu 2023). A 2017 meta-analysis of 18 trials (1,828 people) in unstable angina found fewer heart events and angina symptoms, but 16 of the trials used injections, only 2 used oral forms, and reporting was generally poor (Song 2017).
Safety: in the stroke trial, serious adverse events were similar to placebo (1.0% versus 1.1%) (Wu 2023). The sources here do not describe drug interactions.
We could not find a single published half-life or time to peak for Panax notoginseng that applies to a supplement dose, so we do not list one. Plant extracts are mixtures of many compounds, so no single figure would describe them.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator